Jpmorgan Chase & CO Maia Biotechnology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Maia Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 38 shares of MAIA stock, worth $126. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38
Previous 78
51.28%
Holding current value
$126
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding MAIA
# of Institutions
21Shares Held
661KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA282KShares$938,0010.0% of portfolio
-
Centric Wealth Management67.2KShares$223,7690.05% of portfolio
-
Geode Capital Management, LLC Boston, MA53.3KShares$177,3450.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX45.7KShares$152,1810.0% of portfolio
-
Virtu Financial LLC New York, NY32.5KShares$108,1810.01% of portfolio
About MAIA Biotechnology, Inc.
- Ticker MAIA
- Exchange
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,935,900
- Market Cap $36.4M
- Description
- MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company wa...